Due to the higher bioavailability of fentanyl in FENTORA, when converting patients from other oral fentanyl products, including oral transmucosal fentanyl citrate (OTFC and Actiq(R)), to FENTORA, do not substitute FENTORA on a mcg per mcg basis. Adjust doses as appropriate. (See DOSAGE AND ADMINISTRATION.)
FENTORA is intended to be used only in the care of opioid tolerant cancer patients and only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.
The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.
Full prescribing information about FENTORA, including boxed warning, is available from http://www.FENTORA.com.
About Cephalon, Inc.
Cephalon, Inc. is an international biopharmaceutical company, recently
inducted in to the World Economic Forum Community of Global Growth
Companies. For 20 years, the company has been dedicated to the discovery,
development and commercialization of innovative products in four core
therapeutic areas: central nervous system, pain, oncology and addiction.
Cephalon has delivered a seven-year compound annual growth rate (CAGR)
through 2006 greater than 75% and 2006 revenue of $1.760 billion. A member
of the Fortune 1000, Cephalon currently employs approximately 3,000 people
in the United States and Europe. U.S. sites include the company's
headquarters in Frazer, Pennsylvania, and offices, laboratories or
manufacturing facilities in West Chester, Pennsylvania, Salt Lake City,
Utah, and suburban Minneapolis, Minnesot
|SOURCE Cephalon, Inc.|
Copyright©2007 PR Newswire.
All rights reserved